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Abstract
Duchenne muscular dystrophy (DMD) is a fatal X-linked disorder, character-
ized by progressive skeletal muscle wasting. The disease is caused by various types
of mutations in the dystrophin gene (DMD). The disease occurs at a frequency of
about 1 in 5000 male births, making it the most common severe neuro-muscular
disease. In addition to clinical examinations of muscle strength and function, diag-
nosis of DMD usually involves a combination of immunological assays using muscle
biopsies, typically immunohistochemistry and western blotting, and molecular
techniques such as DMD gene sequencing or Multiplex Ligation Dependent Probe
Amplification (MLPA) using blood samples. In fact, precise molecular diagnosis is a
prerequisite for determining the appropriate personalized therapeutic approach
such as exon-skipping, gene therapy or stem cell-based therapies in conjunction
with gene editing techniques like CRISPR-Cas9. However, the quest for reliable
biomarkers with high sensitivity and specificity for DMD from liquid biopsy is still
a hotspot of research, as such non-invasive biomarker(s) would not only facilitate
disease diagnosis but would also help in carrier detection, which will eventually
result in better disease management. In this chapter, we will illustrate the detailed
current and prospect strategies for disease.
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1. Introduction
Dystrophin protein is present in myocytes in skeletal, cardiac, and smooth
muscles, acting to connect the actin microfilaments, via N-terminus of the protein,
to the extracellular matrix by binding membrane—bound (sarcolemma) glycopro-
tein complex (dystrophin associated glycoprotein complex; DGC) to the C-terminal
end of the protein, and thus, plays an important role in normal muscle function [1].
Inactivating mutations occurring in DMD gene causes immature termination of
protein translation, giving rise to C-terminally truncated protein product that fails
to transmit muscle impulses, which causes increasing intracellular Ca2+ influx and
thus, activating apoptotic machineries and eventually causes cell death and muscle
atrophy/necrosis [2]. Death usually occurs in the third decade of life as a result of
respiratory or heart failure [3].
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2. Methods for DMD diagnosis
2.1 Clinical picture
Affected DMD boys are usually normal at birth but in early childhood they suffer
from inability to get up from floor or climb stairs or run and they fell very often. Also,
enlarged calf muscles (pseudo hypertrophy) are always noticed [4]. From the age of
7–12, the cases become more deteriorated, and the patients start to suffer from
scoliosis [5], and joint contracture [6]. Also, patients will have an apparent reduction
in bone-mineral density and will have hypocalciuria and osteoporosis [7].
Because the disease affects proximal as well as distal muscles, thus, in early
teenage, DMD boys usually get respiratory infections and sleep apnea [8], and
later, the patient will develop cardiomyopathy and eventually heart failure [9].
2.2 Circulating blood biomarkers
2.2.1 CK levels and other proteins/enzymes
One of the dystrophin protein main functions is to stabilize the muscle tissue,
since it exists and binds to sarcolemma. The absence of dystrophin will eventually
lead to the increased permeability of the muscular tissue and consequently the
release of the muscle proteins [10], of which the creatine kinase (CK) enzyme that
is responsible for the production of phosphocreatine and ADP from creatine and
ATP as part of energy homeostasis. In normal condition, normal myocytes turn-
over, serum levels of CK ranges from 20 to 200 U/L, however, it can be slightly
increased in some neurological disorders. On the other hand, in case of DMD boys,
due to the accelerated muscular destruction, it may reach higher levels reaching
several thousands of units/L, and in severe muscle damage it can reach
200,000 U/L [11–13]. However, CK levels sometimes can be misleading because
in advanced stages of DMD, CK levels may come within normal range due to
progressive muscular atrophy [14].
CK is considered one of the most used serum biomarkers in DMD diagnosis,
however, many studies were performed to detect alterations in other muscle related
proteins using immunoassay and MS-based detection to screen for other potential
diagnostic biomarkers (Table 1).
2.2.2 MicroRNA
MicroRNAs (miRNAs) are a tissue—specific class of small, non-coding RNA
molecules that function as gene regulators/silencers and consequently they are
considered sensitive indicators for different cellular contexts. MiRNAs act through
binding to a specific region in the 30-UTR in the target mRNA molecules, thus,
inducing mRNA degradation and inhibiting the translation process [42]. The circu-
lating levels of miRNAs in serum reflect the intracellular status and hence, they are
excellent biomarkers for many pathological conditions as they can be detected from
liquid biopsies and/or tissue specimens [43]. Many studies attempted to study the
modulation in the levels of different miRNAs (Table 2).
2.2.3 Lipids, metabolites, amino acid, and organic acid
In addition to the previously mentioned biomarkers, lipid profile and metabo-
lites in the blood or urine are also very important parameters that reflect the status
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Rare Diseases
Tested marker Levels (high or low) in
DMD patients and/or
other MDs
Location
(serum/muscle)
Detection method Ref.
Alkaline phosphatase
(AP)-A
Elevated in Grade 1 and
Grade 2 patients
Serum Measuring enzyme
activities
[15]
AP-B No change
Gly-AP Elevated in Grade 1 and
Grade 2
Ala-AP Elevated in Grade 1
Ser-AP Elevated in Grade 1,2,3
Leu-AP Elevated in Grade 1
Met-AP No Change
Phe-AP Elevated in Grade 1,2,3
Trp-AP Elevated h in Grade 1,2,3
Gly-pro-AP Elevated in Grade1
Reduced in Grade 3
Gly-Pro-Leu-AP Reduced in Grade1 and
Grade 2
Trypsin Reduced in Grade 1
Cathepsin C Reduced in Grade 1 and
Grade 2
Sulphatase No change
Phosphatase No change
Acetyl-choline esterase Reduced in Grade 2
Esterase Elevated in Grade 1,2,3
RNase Reduced in Grade 1 and
Grade 2
Angiotensin Converting
enzyme
Reduced in Grade 3
Myostatin (Growth and
differentiation factor 8;
GDF8)
Elevated in DMD
patients
Serum ELISA [16]
Interleukin 17 Elevated in Emery-
Dreifuss MD and Limb-
Girdle MD 1B
Serum ELISA [17, 18]
TGF-β2 Elevated in Emery-
Dreifuss MD and Limb-
Girdle MD 1B
IL6 Variable
Skeletal troponin I
(sTnI),
Elevated in DMD, BMD,
LGMD2B
Serum ELISA
Myosin light chain 3
(Myl3),
Elevated in DMD, BMD,
LGMD2B
Fatty acid binding
protein 3 (FABP3)
Elevated in DMD, BMD,
LGMD2B
Muscle-type creatine
kinase (CKM)
Elevated in DMD, BMD,
LGMD2B
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Tested marker Levels (high or low) in
DMD patients and/or
other MDs
Location
(serum/muscle)
Detection method Ref.
N-terminal α
Dystroglycan (αDG-N)
Reduced in DMD
patients
Serum ELISA [19]
Fibronectin Elevated in DMD
Normal in BMD
Serum ELISA [20]
Basic fibroblast growth
factor
Elevated in DMD
patients
Serum ELISA [21]
cardiac myosin light
chain I
Elevated in DMD
patients (correlated with
CK levels)
Serum Immunoradiometric
assay
[22]
Troponin I, fast skeletal
muscle
Elevated in DMD Serum SOMAscan assay
“Aptamer-based
proteomic
technology”
[23]
Carbonic anhydrase 3 Elevated in DMD
Fatty acid-binding
protein, heart
Elevated in DMD
Troponin I, cardiac
muscle
Elevated in DMD
Creatine kinase M-type Elevated in DMD
Mitogen-activated
protein kinase 12
Elevated in DMD
Alanine
aminotransferase 1
Elevated in DMD
Myoglobin Elevated in DMD
Fibrinogen Elevated in DMD
Phospholipase A2,
membrane associated
Elevated in DMD
Acidic leucine-rich
nuclear phosphoprotein
32 family member B
Elevated in DMD
Hepatoma-derived
growth factor-related
protein 2
Elevated in DMD
40S Glucose-6-
phosphate isomerase
ribosomal protein S7
Elevated in DMD
Heparin cofactor 2 Elevated in DMD
Persephin Elevated in DMD
Calcium/calmodulin-
dependent protein
kinase II α
Elevated in DMD
Malate dehydrogenase,
cytoplasmic
Elevated in DMD
l-lactate dehydrogenase
B chain
Elevated in DMD
Aminoacylase-1 Elevated in DMD
Proteosome subunit α
type-2
Elevated in DMD
4
Rare Diseases
Tested marker Levels (high or low) in
DMD patients and/or
other MDs
Location
(serum/muscle)
Detection method Ref.
C-X-C motif chemokine
10
Elevated in DMD
cAMP-dependent
protein kinase catalytic
subunit α
Elevated in DMD
Heat-shock 70 kDa
protein 1A/1B
Elevated in DMD
Proto-oncogene
tyrosine-protein kinase
receptor Ret
Reduced in DMD
Growth/differentiation
factor 11
Reduced in DMD
Complement decay-
accelerating factor
Reduced in DMD
Cadherin-5 Reduced in DMD
Tumor necrosis factor
receptor superfamily
member 19 L
Reduced in DMD
Gelsolin Reduced in DMD
Wnt inhibitory factor 1 Reduced in DMD
Contactin-5 Reduced in DMD
Prolyl endopeptidase
FAP
Reduced in DMD
Jagged-1 Reduced in DMD
Netrin receptor UNC5C Reduced in DMD
Kunitz-type protease
inhibitor 1
Reduced in DMD
Protein SET Reduced in DMD
Disintegrin
metalloproteinase
domain-containing
protein 9
Reduced in DMD
Cell adhesion molecule
L1-like
Reduced in DMD
Osteomodulin Reduced in DMD
WAP, Kazal, Ig, Kunitz
and NTR domain-
containing protein 1
Reduced in DMD
Bone sialoprotein 2 Reduced in DMD
Interleukin-34 Reduced in DMD
Neurogenic locus notch
homolog protein 3
Reduced in DMD
Cytoplasmic aspartate
aminotransferase
Elevated in DMD Serum Measuring enzyme
activity
[24]
mitochondrial aspartate
aminotransferase
Elevated in DMD
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Tested marker Levels (high or low) in
DMD patients and/or
other MDs
Location
(serum/muscle)
Detection method Ref.
Alanine transaminase
(ALT)
Elevated in DMD Serum ELISA [25]
Aspartate transaminase
(AST)
Elevated in DMD
Muscle-specific enolase
(MSE, beta beta and
alpha beta enolases)
Elevated in DMD and
another progressive
muscular dystrophies
Serum Enzyme
immunoassay
[26]
Serum carbonic
anhydrase III (CA-III)
Elevated in DMD, limb-
girdle dystrophy,
facioscapulohumeral
dystrophy and congenital
dystrophy
Serum Enzyme
immunoassay
[27]
Creatine kinase (CK)
isoenzymes (MM, MB,
and BB)
Elevated in DMD Serum Sensitive enzyme
immunoassay
[28]
Matrix
metalloproteinase-9
(MMP-9)
Elevated in DMD Serum ELISA [29]
Tissue inhibitors of
metalloproteinase-1
(TIMP-1)
Elevated in DMD
Osteopontin (OPN) Normal
MT-1-MMP Elevated in autosomal
dominant EDMD
Serum ELISA and
zymography
[30]
MMP2 Elevated in autosomal
dominant EDMD and in
X-linked EDMD
MMP9 Non-significant
elevation
TIMP-1 Normal in AD-EDMD
Elevated in X-linked
EDMD
Serum ELISA sandwich
immunoassay
[31]
TIMP-2 Non-significant decrease
AD-EDMD/X-EDMD
cases
TIMP-3 Reduced in AD-
EDMD/X-EDMD
Carbonic anhydrase III
(CA-III, EC 4.2.1.1)
Elevated in DMD,
congenital (Fukuyama-
type), limb-girdle, also
elevated in: polymyositis
myotonic dystrophy
amyotrophic lateral
sclerosis spinal
progressive muscular
atrophy or Kugelberg-
Welander disease and in
carriers of DMD
Serum Radioimmunoassay [32]
Vitamin D binding
protein (GC)
Reduced in DMD Serum 2D-HPLC off-line
coupled to LC-
MALDI-TOF-MS
verified with ELISA
[33]
Fibulin-1 (FBLN1) Elevated in DMD
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Tested marker Levels (high or low) in
DMD patients and/or
other MDs
Location
(serum/muscle)
Detection method Ref.
Gelsolin (GSN) Reduced in DMD
Carbonic anhydrase 1
(CA1)
Elevated in DMD
Apolipoprotein B100 Reduced in DMD
ALT, AST, LDH, and
ALP
Elevated in DMD Serum Enzymatic assay [34]
ALT, AST, and LDH Elevated in BMD and
LGMD
FSHD and EDMD lack of abnormal serum
enzyme levels
ALP Highly elevated in
LGMD2B
Elevated in non-
LGMD2B
Vascular endothelial
growth factor
Highly elevated in BMD
Elevated in Bedridden
DMD, spinal muscular
atrophy, myotonic
dystrophy
Serum ELISA [35]
Creatine kinase MB
fraction
Elevated in DMD Serum Multiplex,
microsphere-based
immune-fluorescent
assay
[36]
Tissue-type
plasminogen activator
PLAT
Slightly elevated in DMD
Myoglobin Slightly elevated in DMD
Epidermal growth
factor
Slightly elevated in DMD
Chemokine (C-C motif)
ligand 2
Slightly elevated in DMD
CD 40 ligand Slightly elevated in DMD
Vitronectin Slightly elevated in DMD
Carboxyterminal
propeptide of type I
procollagen
No significant alteration Serum Radioimmunoassay [37]
Aminoterminal
propeptide of type III
procollagen
No significant alteration
Laminin P1 No significant alteration
Creatine kinase Elevated in DMD and
BMD
Serum Measuring enzyme
activity
[38]
Pyruvate kinase Elevated in DMD and
BMD
Myosin light chain—3 Elevated in DMD Serum affinity proteomics-
based screening
approach using an
antibody suspension
bead array
[39]
Carbonic anhydrase III Elevated in DMD
Electron transfer
flavoprotein A
Elevated in DMD
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of the muscles and thus, they could be measured to indicate the extent of muscular
dystrophy and can serve as good candidates for diagnostic purposes (Table 3).
2.3 Muscle imaging
Magnetic resonance imaging (MRI) is now used to visualize the composition of
skeletal muscles and detect structural abnormalities in the of DMD patients [61].
The produced images can reveal the presence of fat infiltration of muscle tissue, a
characteristic consequence of DMD, and thus, can be used for monitoring disease
progression and response to treatment [62].
2.4 Genetic diagnosis
2.4.1 RFLP
Detecting the mutation, especially non-sense point mutations, in the 2.4 Mb
gene represents a challenging task. In this context, restriction fragment length
polymorphism (RFLP) analysis could be used by digesting the genomic DNA using
specific restriction endonucleases followed by Southern blotting using DMD-
specific DNA probes (genomic or cDNA probes). At 1985, Bamkan et al. developed
11 RELP markers that are present in the X chromosome and can be used for
diagnosis. However, RFLP can detect only small percentage of the mutation and
hence it cannot be used as gold standard technique in the diagnosis process [63–65].
2.4.2 Multiplex PCR
Multiplex PCR is one of the modified PCR protocols that allows the co-
amplification of multiple products using different primer pairs that specially bind
complementary regions in the target segment. This method showed a great potential
Tested marker Levels (high or low) in
DMD patients and/or
other MDs
Location
(serum/muscle)
Detection method Ref.
Mitochondrial malate
dehydrogenase 2
Elevated in DMD
Electron transfer
flavoprotein B
Reduced in DMD
Fast skeletal muscle
troponin T
Elevated in DMD
Matrix
metalloproteinase 9
Elevated in DMD Serum Immunoassay [40]
Matrix
metalloproteinase 2
Reduced in BMD
Myostatin (GDF-8) Reduced in DMD
Follistatin (FSTN) Elevated in DMD and
BMD
N-terminal fragment of
titin
Elevated in DMD
patients
Urine ELISA [41]
Table 1.
List of potential protein biomarkers that could be utilized in the diagnosis of Duchenne muscular dystrophy.
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microRNA Status Disease Location Ref.
miR-133a Upregulated DMD, BMD,
LGMD, FSHD
Serum and
skeletal
muscles
[44–47]
miR-206 Upregulated DMD, BMD,
LGMD, FSHD
Serum and
skeletal
muscles
miR-1 Upregulated DMD, BMD,
LGMD, FSHD
Serum and
skeletal
muscles
miR-499 Upregulated DMD Serum [45]
miR-208a Upregulated DMD Serum
miR-208b Upregulated DMD Serum
miR-95 Upregulated DMD Serum [48]
miR-539 Downregulated DMD Serum
miR-30c Upregulated DMD Serum [49]
miR-181a Upregulated DMD Serum
miR-21 Downregulated DMD Urine [50]
miR-29 Downregulated DMD Urine
miR-23 Downregulated DMD Urine
miR-181a Upregulated DMD Serum [51]
miR-4538 Upregulated DMD Serum
miR-4539 Upregulated DMD Serum
miR-606 Upregulated DMD Serum
miR-454 Downregulated DMD Serum
miR-483 Upregulated DMD Serum [52]
hsa_miR_146b, hsa_miR_368, hsa_miR_381,
hsa_miR_487b, hsa_miR_495, hsa_miR_376a,
hsa_miR_299_5p, hsa_miR_155, hsa_miR_382,
hsa_miR_199a, hsa_miR_379, hsa_miR_335,
ambi_miR_5021, hsa_miR_432, hsa_miR_199b,
hsa_miR_369_5p, hsa_miR_21, hsa_miR_34a,
hsa_miR_199a*, hsa_miR_154, hsa_miR_221,
hsa_miR_214, hsa_miR_518a_2*,
hsa_miR_409_3p, hsa_miR_452,
ambi_miR_2537, hsa_miR_127,
hsa_miR_493_3p, hsa_miR_130a,
ambi_miR_4983, ambi_miR_13145,
hsa_miR_148a, hsa_miR_210,
hsa_miR_485_5p, hsa_miR_299_3p,
hsa_miR_134, hsa_miR_222, hsa_miR_181d,
ambi_miR_13258
Upregulated DMD Serum [53]
hsa_miR_423, hsa_miR_361, hsa_miR_197,
hsa_miR_92, hsa_miR_26a, ambi_miR_7075,
hsa_miR_30b, hsa_miR_30e_5p, hsa_miR_29a,
ambi_miR_13156, hsa_miR_30a_5p,
hsa_miR_193b, hsa_miR_331, hsa_miR_486,
hsa_miR_30d, hsa_miR_29b, hsa_miR_101,
hsa_miR_30c, hsa_miR_22
Downregulated
Table 2.
List of different microRNAs that could be used as potential biomarkers in the diagnosis of DMD.
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Tested marker Levels (high or low) Location
(serum/
muscle)
Ref.
24,25(OH)2D3 Reduced in DMD Serum [54]
1,25(OH)2D3 No change
25(OH)D3 No change
Creatinine Reduced in DMD, BMD, LGMD2A
and LGMD2B
Serum [55]
Imidazole acetic acid Reduced in DMD and LGMD2B
5α Dihydrotestosterone glucuronide //
androsterone glucuronide // Etiocholan-
3alpha-ol-17-one 3-glucuronide
Reduced in DMD
DL-p-Hydroxyphenyllactic acid //
Isohomovanillic acid
Reduced in DMD
Creatine Elevated in DMD, DM1,
LGMD2Aand LGMD2B
Guanidinoacetic acid Reduced in DMD, BMD, DM1 and
LGMD2A
p-Coumaric acid Reduced in DMD
Citrulline Reduced in DMD
5-Methoxyindoleacetate // Indoleacetic
acid
Reduced in DMD
L-Aspartic acid Reduced in DMD
Ornithine Reduced in DMD
2-Hydroxycaproic acid Reduced in DMD
L-Serine Reduced in DMD
Dehydroisoandrosterone 3-sulfate Reduced in DMD
Erythrose Reduced in DMD, BMD, FSHD
Glutamine Reduced in DMD, BMD, LGMD-
2B, FSHD and elevated in DM-1
Serum [56]
Acetate Elevated in DMD, BMD, FSHD,
LGMD-2B and DM-1
Tyrosine Elevated in BMD
Lysine Reduced in FSHD, LGMD-2B and
DM-1
Citrate Reduced in FSHD
Elevated in LGMD-2B
Lactate Reduced in LGMD-2B
Histidine Reduced in FSHD
Serum creatinine Elevated in BMD
Decreased in DMD
Serum [57]
3-Methylhistidine Deduced in DMD and LGMD Urine [58]
N epsilon,N epsilon-dimethyllysine No alteration
N epsilon, N epsilon, N epsilon-
trimethyllysine
No alteration
NG,NG-dimethylarginine Elevated in DMD and LGMD
NG,N’G-dimethylarginine No alteration
10
Rare Diseases
to diagnose DMD since the multiple primers covered commonly mutated locations
across the entire DMD gene, hotspot regions [66–68]. This technique was first
developed by Chamberlain et al. [69] through utilization of 6 primer sets that were
modified to 9 sets and later to 10 by Beggs et al. [70] (to amplify exons 45, 48, 19,
17, 51, 8, 12, 44, 4). If no amplification take place, this will confirm deletion of this
exon. The developed primer sets were successfully able to detect deletion mutations
in the hot spot regions. One of the limitations of such technique was its inability to
diagnose all cases with other deletion mutation in other regions, or patients with
SNPs or deep intronic mutation.
2.4.3 Multiplex ligation dependent probe amplification (MLPA)
In order to simultaneously investigate the status of the 79 exons of the DMD
gene, a PCR-based technique was developed to diagnose DMD in a multiplex PCR
reaction. The assay uses multiple probes to target different exons in the DMD gene.
Each probe consists of two oligonucleotides; one consists of a 50-adapter and a
30-exon-specific region, and vice versa for the second oligonucleotide, where the
30-end of the first primer and the 50-end of the second hybridize to two adjacent
nucleotides in the target exon. Hybridized probes are subjected to ligation reaction,
thus, only hybridized probes get ligated, amplified by PCR using adapter-specific
primers and separated by capillary electrophoresis. Positive PCR product indicates
the presence of the target exon, while deleted exon(s) will not produce
corresponding product(s). In this assay, it is also possible to detect exon duplica-
tion, which will be detected as larger peak [71, 72]. However, this assay cannot
detect non-sense nor in/del point mutations.
2.4.4 Microarray
High-throughput methods such as DNAmicroarrays were adopted using specific
oligonucleotide probes that cover the entire 2.4 mbp DMD gene (targeted high
density comparative genomic hybridization (CGH) microarray). Such method
could effectively be used to detect known as well as novel intronic mutations
[73–75].
2.4.5 Next generation sequencing (NGS)
The development of NGS and the massively parallel sequencing allowed the
sequencing of 100 s of millions of independent short reads (100–300 bp) at the
same time. Such approaches generate huge amount of data that uses bioinformatic
analysis for annotations and alignments of the generated sequences to produce
sequence information for large genes such as DMD and titin and delineate the exact
locations of mutations [76]. One major advantage of resorting to NGS for DMD
diagnosis is that it could be used for the analysis of MLPA-negative samples that
could have small deletions/duplications or single nucleotides variants [77].
Tested marker Levels (high or low) Location
(serum/
muscle)
Ref.
Tetranor PGDM (PGD2 metabolite) Elevated in DMD Urine [59]
Nitric oxide Reduced in DMD Serum [60]
Table 3.
List of metabolites that can be used as potential biomarkers in DMD diagnosis.
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Also, RNA sequencing by NGS (RNA-seq) is very useful in detecting the splicing
pattern that occur in the DMD transcripts in the muscles through different devel-
opmental stages, muscle breakdown or muscle regeneration [78–80].
2.4.6 Muscle biopsy
In some cases, muscle biopsy is required to fully characterize the phenotypic
effect of the mutation. The muscle tissue is used in immunoassays, using different
antibodies targeting different regions of dystrophin protein (C-terminal, Rod and
N-terminal domains), such as western blotting [81–83] or immunohistochemistry
[83]. Uchino et al. [83] developed a multiplex western blotting assay to analyze the
expression of other muscle proteins like dysferlin, merosin, different forms of
sarcoglycan (alpha, beta, gamma, delta), and calpain in addition to dystrophin
protein, due to the frequent epigenetic changes incited in these proteins as
a consequence to the alteration in dystrophin expression.
3. Conclusion
In this chapter, we have presented a comprehensive review for the methods that
have been used in the diagnosis of DMD. Because of the nature of the disease, an
X-linked disorder, DMD symptoms of the first affected male births of asymptom-
atic carrier mothers are usually go unnoticed until the age of 5, where the progres-
sive muscle weakness becomes obvious and fibrotic fatty tissue infiltration is
prominent. However, it is well known that early diagnosis and treatment results in
better disease management and improve the clinical outcomes. In fact, some studies
have pointed out to the fact that initiating corticosteroids therapy early enough has
delayed the loss of ambulation in most cases by about 2 years [84]. In addition, with
the fast-paced progress in molecular/personalized therapies such as exon-skipping
and gene-editing based approaches, precise diagnosis and mutation detection
becomes a necessity. Moreover, the genetic testing has been extensively used in
prenatal diagnosis and has assisted in decreasing disease burden by aborting
affected male pregnancies. In a retrospective study conducted in the Netherland,
the authors reported 145 abortions of male fetuses over 26 years that had been
found to carry inactivating mutations of the DMD gene [85]. Furthermore, identi-
fying female carriers, is gaining momentum to decrease the possibility of giving
birth to affected males and consequently contributes to the overall disease
management.
12
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